Use of #baloxavir as adjunctive #antiviral #therapy to neuraminidase inhibitors in severely immunocompromised individuals infected with #influenza

Nature Comms: Baloxavir outperforms oseltamivir, favipiravir, and amantadine in treating lethal influenza A(H5N1) HA clade 2.3.4.4b infection in mice

  CDC Influenza Antiviral Medications:  Summary for Clinicians - Jan 2026 #19,062 During any novel influenza pandemic - even one as long ant...

#Baloxavir outperforms #oseltamivir, #favipiravir, and #amantadine in treating lethal #influenza #H5N1 HA clade 2.3.4.4b #infection in #mice

Impaired #host shutoff is a fitness cost associated with #baloxavir marboxil #resistance #mutations in #influenza A virus PA/PA-X nuclease domain

#Oseltamivir and #baloxavir monotherapy and combination #therapy efficacy against clade 2.3.4.4b #H5N1 #influenza virus infection in #ferrets

Comprehensive evaluation of #therapeutic #effectiveness and #safety profiles of #baloxavir marboxil for managing #influenza virus infection in #pediatric populations: a systematic #review with pooled meta-analytic data

Evaluation of #therapeutic effect of #baloxavir marboxil against high pathogenicity avian #influenza virus infection in #duck model

Impaired host shutoff is a #fitness cost associated with #baloxavir marboxil #resistance mutations in #influenza A virus PA/PA-X nuclease domain.

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023

Efficacy of #baloxavir marboxil against #bovine #H5N1 virus in mice